1. Home
  2. FAX vs OMER Comparison

FAX vs OMER Comparison

Compare FAX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Asia-Pacific Income Fund Inc.

FAX

abrdn Asia-Pacific Income Fund Inc.

SELL

Current Price

$12.67

Market Cap

532.5M

Sector

Finance

ML Signal

SELL

Logo Omeros Corporation

OMER

Omeros Corporation

SELL

Current Price

$16.69

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FAX
OMER
Founded
1986
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
532.5M
1.2B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
FAX
OMER
Price
$12.67
$16.69
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $27.50
AVG Volume (30 Days)
213.7K
★ 875.8K
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 12.09%
N/A
EPS Growth
N/A
★ 98.15
EPS
N/A
★ 0.77
Revenue
N/A
★ $29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$73.59
P/E Ratio
★ N/A
$22.78
Revenue Growth
★ N/A
N/A
52 Week Low
$12.57
$6.70
52 Week High
$16.37
$21.24

Technical Indicators

Market Signals
Indicator
FAX
OMER
Relative Strength Index (RSI) 41.05 45.32
Support Level $12.59 $16.33
Resistance Level $14.69 $19.68
Average True Range (ATR) 0.16 0.89
MACD 0.02 0.00
Stochastic Oscillator 9.26 17.05

Price Performance

Historical Comparison
FAX
OMER

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: